Institut National De La Sante Et De La Recherche Medicale

Assistance Publique-hopitaux De Paris

Institut Gustave Roussy

Centre Henri Becquerel

UniversitÉ Paris Descartes

Université Paris—sud

Other

Université Pierre Et Marie Curie (Paris 6)

Université Pierre Et Marie Curie

Université Paris-Sud 11

Erasmus Universiteit Rotterdam

Christian Bastard

William Vainchenker

Olivier Bernard

Michaela Fontenay

Franck Viguie

Francois Delhommeau

Anthonie Willem Langerak

Michael Hummel

Eduardus Maria Dominicus Schuuring

Elizabeth Anne Macintyre

Michael Kneba

Paul Anthony Stuart Evans

Gareth John Morgan

John Lewis Smith

Antonio Parreira

Ramon Garcia Sanz

Frances Louise Lavender

Jesus Fernando San Miguel

Frederic Bernard Louis Davi

Monika Brüggemann

Jesus Fernando San Miquel

Ramon Garzia Sanz

François Delhommeau

The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO: 2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour.

TET2 as a diagnostic and pronostic marker in hematopoietic neoplasms

TET2 as a diagnostic and prognostic marker in hematopoietic neoplasms

The invention relates to PCR-based clonality studies for among others early diagnosis of lymphoproliferative disorders. Provided is a set of nucleic acid amplification primers comprising a forward primer, or a variant thereof, and a reverse primer, or a variant thereof, capable of amplifying a rearrangement selected from the group consisting of a VH-JH IGH rearrangement, a DH-JH IGH rearrangement, a VK-J&#x3ba; IGK rearrangement, a VK/intron-Kde IGK rearrangement, a V&#x3bb;-J&#x3bb; IGL rearrangement, a V&#x3b2;-J&#x3b2; TCRB rearrangement, a D&#x3b2;-J&#x3b2; TCRB rearrangement, a V&#x3b3;-J&#x3b3; TCRG rearrangement, a V&#x3b4;-J&#x3b4; TCRD rearrangement, a D&#x3b4;-D&#x3b4; TCRD rearrangement, a D&#x3b4;-J&#x3b4; TCRD rearrangement, a V&#x3b4;-D&#x3b4; TCRD rearrangement, or a translocation selected from t(11;14)(BCL1-IGH) and t(14;18)(BCL2-IGH). The primers can be used in PCR-based clonality studies for early diagnosis of lymphoproliferative disorders and detection of minimal residual disease (MRD). Also provided is a kit comprising at least one set of primers of the invention.

Nucleic acid amplification primers for PCR-based clonality studies

The present invention concerns an in vitro method for diagnosing a myeloid tumor or a lymphoid tumor in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO:2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumor or a lymphoid tumor.

TET2 as a new diagnostic and pronostic marker in hematopoietic neoplasms

The invention relates to PCR-based clonality studies for among others early diagnosis of lymphoproliferative disorders. Provided is a set of nucleic acid amplification primers comprising a forward primer, or a variant thereof, and a reverse primer, or a variant thereof, capable of amplifying a rearrangement selected from the group consisting of a VH-JH IGH rearrangement, a DH-JH IGH rearrangement, a VK-JK IGK rearrangement, a VK/intron-Kde IGK rearrangement, a V&#x3bb;-J&#x3bb; IGL rearrangement, a V&#x3b2;-J&#x3b2; TCRB rearrangement, a D&#x3b2;-J&#x3b2; TCRB rearrangement, a V&#x3b3;-J&#x3b3; TCRG rearrangement, a V&#x3b4;-J&#x3b4; TCRD rearrangement, a D&#x3b4;-D&#x3b4; TCRD rearrangement, a D&#x3b4;-J&#x3b4; TCRD rearrangement, a V&#x3b4;-D&#x3b4; TCRD rearrangement, or a translocation selected from t(11;14)(BCL1-IGH) and t(14;18)(BCL2-IGH). The primers can be used in PCR-based clonality studies for early diagnosis of lymphoproliferative disorders and detection of minimal residual disease (MRD). Also provided is a kit comprising at least one set of primers of the invention.

Growing community of inventors

Ardouval, France

Christian Bastard